Featured Research

from universities, journals, and other organizations

Surgical Technique Helps To Reanimate Paralyzed Faces

Date:
July 17, 2007
Source:
JAMA and Archives Journals
Summary:
A surgical technique known as temporalis tendon transfer, in conjunction with intense physical therapy before and after surgery, may help reanimate the features of those with facial paralysis, according to a report in the July/August issue of Archives of Facial Plastic Surgery, one of the JAMA/Archives journals.

A surgical technique known as temporalis tendon transfer, in conjunction with intense physical therapy before and after surgery, may help reanimate the features of those with facial paralysis, according to a report in the July/August issue of Archives of Facial Plastic Surgery, one of the JAMA/Archives journals.

"The rehabilitation of facial paralysis is one of the greatest challenges faced by reconstructive surgeons today," the authors write as background information in the article. "It is an unfortunate fact that there is no ideal procedure that leads to the return of fully normal facial function. Furthermore, every case of facial paralysis is different in the cause of the paralysis, the degree and location of the paralysis and the resulting condition of the facial musculature and surrounding soft tissue envelope." Many patients have excessive movement in some areas of the face and no movement in others; as a result, surgeons treating this condition must be able to perform multiple types of procedures and understand the underlying neurologic dysfunction.

Patrick J. Byrne, M.D., and colleagues at The Johns Hopkins University School of Medicine, Baltimore, report the results of seven facial paralysis patients treated with temporalis tendon transfer. This technique typically involves an incision beginning at the ear and ending 3 to 4 centimeters into the hairline at the temple. The temporalis muscle, a fan-shaped muscle on the side of the head, is cut at the point that it connects to the jawbone and released from the tissue surrounding it. Then, it is stretched to the point where the muscles of the mouth join together. The tendon that previously connected the temporalis muscle to the jawbone is cut free and then stretched horizontally for 3 to 4 centimeters; it is sutured to the surrounding muscles and deep skin tissue. Physical therapy to retrain facial muscles begins before the surgery and continues beginning seven days after the procedure.

At a minimum of four months after the surgery, "patient satisfaction was very high," the authors write. "Of a possible 10 points, patients reported mean [average] satisfaction with appearance of 8.4, with feeding of 8.1, with speech of 8.7 and with smile function of 7.1." Photographs taken of the patients were graded by 21 physicians in the Johns Hopkins Department of Otolaryngology--Head and Neck Surgery. "Four patients were physician-graded as excellent to superb. The other three patients were rated as having good postoperative results."

Movement in each patient's mouth muscles was assessed by measuring the position of the muscles at rest and again when the patient contracted just the temporalis muscle. Movement was identified in all patients following the procedure, with measurements ranging from 1.6 millimeters to 8.5 millimeters and an average of 4.2 millimeters.

"Temporalis tendon transfer is a relatively easy procedure to perform that has distinct advantages compared with other forms of facial reanimation and provides very good results," the authors conclude. These advantages include its immediate effect, the ease with which the tendon is harvested and transferred and the predictability of the outcomes. "This procedure results in improved form and function, may often be performed in a minimally invasive manner and eliminates the facial asymmetry typically produced by temporalis transfer," a similar procedure in which only the temporalis muscle is moved.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Cite This Page:

JAMA and Archives Journals. "Surgical Technique Helps To Reanimate Paralyzed Faces." ScienceDaily. ScienceDaily, 17 July 2007. <www.sciencedaily.com/releases/2007/07/070716190910.htm>.
JAMA and Archives Journals. (2007, July 17). Surgical Technique Helps To Reanimate Paralyzed Faces. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/07/070716190910.htm
JAMA and Archives Journals. "Surgical Technique Helps To Reanimate Paralyzed Faces." ScienceDaily. www.sciencedaily.com/releases/2007/07/070716190910.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins